Suzanne Cole, MD, FACP, FASCO

Caring for patients with cancer and blood disorders. Passionate about increasing patient access to clinical trials in the community setting. #Wolfpack

[Baqir Jafry, MD @BaqirJafryMD]

Grateful my path crossed with Dr. @SuzanneColeMD @ASCO after an excellent session on early career paths in clinical practice and hospital/community oncology.

Her insights on molecular onc, clinical trials, and expanding access to high-quality cancer care were truly inspiring!

[MJ @MonikaJoshimd]

Congratulations to ⁦@KMittalmd⁩ and team for delivering her talk in the symptom management track #ASCO25 ⁦@PGrivasMDPhD⁩ ⁦@SuzanneColeMD⁩

[UroToday.com @urotoday]

Surgical outcomes of radical nephrectomy and inferior vena cava thrombectomy following preoperative systemic immunotherapy: a propensity score analysis. #AuthorCommentary on UroToday > https://t.co/GmQqQTo7Fq @ZineEddineKhene @UroRajB @wadihissa1 @DrWoldu @GastonKris @HHammersMD @SuzanneColeMD @TiansterZhang @kbensalah35 @ylotan

[Michael Serzan, MD @MikeSerzanMD]

🗣️Bladder Rapid Oral Abstracts #ASCO25

👉Abs4520: Dr @FaltasLab presenting #abemaciclib cis-ineligible MIBC on #CLONEVO

🩺Clinical implications:
- Preoperative #abemaciclib in MIBC demonstrated promising efficacy and tolerability while modulating cell cycle-dependent pathways
- Consider future studies in combination with ADCs (EV/P)

-------------------------------------------------------
n = 20 (16/20 males)
5/20 cT4.
3 didn't undergo RC, 1 withdrew consent.

💉abema (200mg BID PO) x 4-8 weeks prior to RC

✅ pCR = 18.8% (3/16)
✅ downstaging = 31.3% (5/16)

⚠️G3 TRAE anemia (4/20), abdominal pain (1/20) and diarrhea (1/20)

🩻 Imaging Mass Cytometry of pre/post 👇 RB1 phosphorylation
🧬 VAF 👇after abema by 20.5% (p = 0.04)
🧬 ctDNA tumor fraction(TF)👇after abema by 28.6%
⭐️Pt w/ CCND1 amplification most significant decrease in TF (63.8%) highlighting CCND1 as a potential response biomarker

👥@DrRosenbergMSK @MichvdHeijden @FaltasLab @SuzanneColeMD @cnsternberg @MattGalsky @bergsa83 @alantanmd @tompowles1 @DrKarieRuncie @BraunMDPhD @PGrivasMDPhD @shilpaonc @AmandaNizamMD @DrKarineTawagi @DrYukselUrun @ReneeSaliby @drenriquegrande @bavilima @DRBakaloudiMD @ReginaBarCar @crisbergerot @kidneycan @KidneyCancer @ASCO @OncoAlert @OncBrothers @OncLive @BladderCancerUS

[KMittaloncMD @KMittalmd]

@MonikaJoshimd @PGrivasMDPhD @SuzanneColeMD 🙏 @MonikaJoshimd
As immunotherapies expand their presence, and as we develop novel combinations through our ECOG GU committee, building teams for #irAE management in the real world is critical!

[PrECOG @PrECOGonc]

#RealWorldData research study PrE1702, led by @SuzanneColeMD of @utswcancer, aims to discover if osimertinib +/- chemotherapy has the same benefits for patients receiving treatment outside of a #ClinicalTrial as for those in a trial. Learn more: https://t.co/OIWah87i9t

[Horizon CME @HorizonCME]

📣We're looking forward to Best of ASCO® Dallas with planning committee member Dr. @SuzanneColeMD (of @utswcancer)!

Join us for this Official Annual Meeting Review of the American Society of Clinical Oncology® (ASCO®) - this August 2-3rd.
🌐 REGISTER TODAY: https://t.co/RZKodj0iYe

#BestOfASCO #OncologyUpdates #CancerCareInnovation #ASCOReview #ClinicalOncologyEducation #OncologyResearchHighlights #PracticeChangingData #ASCO25 #ASCO2025

[ASPIRE Community of Practice @ASPIRE_CoP]

Spread the word! @KMittalmd @MazieTsangMD @DeepikaDevuniMD @VKazakovaMD @OncBrothers @drtulsijose @SuzanneColeMD

[Jasmine Kamboj, MD, FASCO @JasmineKambojMD]

#ASCO25

Amazing to be able to start ASCO Day 1 with families and friends (who are like family)-
✅we presented the KAMBOJ-CHRISTIE Family & friends and MSCO BOARD YIA Award
✅shared my story with the IMG CoP
✅got the Yvonne Award for community oncology by @oncodaily
✅connected with my LDP Group
@MayoCancerCare @MayoHemeOnc @lynn_schuchter @DrChoueiri @NazliDizman @ZiadBakouny @SuzanneColeMD @oncologyCOA @PatelOncology @KristenCiombor @GevTamamyan

[Dr. Bishoy M. Faltas @FaltasLab]

Beyond excited to present the results of our investigator-initiated #CLONEVO trial at #ASCO25 @ASCO! 🏢Arie Crown Theater on May 31, 2025 🕐

Only 4 weeks of pre-op abemaciclib in patients with cisplatin-ineligible MIBC resulted in:

✅ 31% pathologic downstaging

✅ Clear on-target activity through ⬇️ Rb phosphorylation & Ki67. Measured by spatial immune mass cytometry in more than 630,000 single cells from matched pre-/post-abemaciclib tissues 🔬

🩸🧪 Serial ctDNA analysis shows tumor fraction reduction was driven by abema, not TURBT

☑️Tumors with CCND1 ⭕️ amplification are more likely to respond (very cool underlying biology!)

⬇️ decreased expression of critical DNA damage proteins TOBP1 and RAD51. Providing rationale for testing sequencing CDK4/6 inhibitors after DNA-damaging therapies, including ADCs, to inhibit cancer cells from repairing double-strand DNA breaks

https://t.co/omrwyHhKJd

@MHosmanMD @cnsternberg @DoctorMargolis @DrJonesNauseef @DrAnaMolina @DrDavidNanus @rohitjainMD @scientistatlrge @DrMhidalgo @notSoJunkDNA @willbfx @ElementoLab @SuzanneColeMD @DrScottTagawa #clinicaltrials #teamscience

[Jasmine Kamboj, MD, FASCO @JasmineKambojMD]

Thanks to @SuzanneColeMD of @UTSouthwestern for interviewing with me for @oncodaily’s podcast - #EMPOWERINGONCOLOGISTS

✅Great insights as to how you established a research infrastructure in a community setting.
✅how you navigated through life making choices that were not the usual but very apt for your career and personal life trajectory.
✅And how leadership can bring its own challenges and you successfully handled them and utilized coaching as a tool.
@HemOncFellows
@HemOncWomenDocs
@IMG_Oncologists
@oncologyCOA

https://t.co/IFFQsGpmD9

[Petros Grivas @PGrivasMDPhD]

Fantastic to see colleagues & friends @AmerUrological discussing science, patient care, research & beyond! @UroDocAsh
@DrRosenbergMSK @JCensits @AdityaBagrodia @bavilima @siadaneshmand @JoshMeeks @SuzanneColeMD @spsutkaMD @yawnyame @DanLinMD @UrogerliMD
@shilpaonc @virajmaster

[Dr. Bishoy M. Faltas @FaltasLab]

Thanks @TiansterZhang @SuzanneColeMD for your support and being amazing collaborators in this trial! #teamscience

[Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang]

#SOAR is an important trial for oligomet radiation in #kidneycancer, led by our wonderful @utswcancer colleagues @SuzanneColeMD @Raquib_Hannan @ASCO #GU25

[PrECOG @PrECOGonc]

#RealWorldData registry study PrE1702, led by @SuzanneColeMD of @utswcancer, aims to discover if osimertinib +/- chemotherapy has the same benefits for patients receiving treatment outside of a #ClinicalTrial as for those in a trial. Learn more: https://t.co/OIWah87i9t

[Amanda Nizam, MD @AmandaNizamMD]

Congratulations, @EMittendorfMD, @n8pennell, @ErikaHamilton9, @SoniSmithMD, and all others elected!

Especially proud of @SuzanneColeMD & @DrRanaMcKay, who have been consistently exceptional leaders and aspirational role models to many of us in GU Oncology! @ASCO @CleClinicMD

[Nathan A. Pennell MD, PhD, FASCO @n8pennell]

Congratulations to @EMittendorfMD and new Board members @SoniSmithMD and Melissa Dillmon, and Nominating Cmt members @ErikaHamilton9 @SuzanneColeMD and Rana McKay!

So excited to join the @ASCO Board with such a great group and a huge thank you to all who supported me!

[KMittaloncMD @KMittalmd]

The day GU oncologists decided to go to the thoracic committee to show our support for ⁦⁦@SuzanneColeMD⁩ real world trial. ⁦Real world data for real world patients ⁦@HamidEmamekhoo⁩ ⁦@eaonc⁩ ⁦⁦@UMassCancerCtr⁩

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Real World Data Working Group 11/8/24 @eaonc Fall Meeting - @SuzanneColeMD #lcsm #PrecisionMedicine #RWD PrE1702

[PrECOG @PrECOGonc]

PrE1702 study chair @SuzanneColeMD explains why our new #RealWoldData #RegistryStudy is so important at the @eaonc Fall 2024 Group Meeting. Learn more: https://t.co/QHNC5fHO0R